SEC Form 4 · accession 0001127602-15-005041
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Northcott
Officer — VP, Marketing, Comm Strategy
Period of report
Feb 5, 2015
Accepted (ET)
Feb 9, 2015 · 4:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units (Phantom Stock)F1,F2 | — | Feb 5, 2015 | A | 120,600 | A | — | — | Common Stock | 120,600 | 120,600 | D |
| Stock Option (Right to Buy)F3 | $0.89 | Feb 5, 2015 | A | 482,400 | A | — | Feb 5, 2025 | Common Stock | 482,400 | 482,400 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter.
- F3Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/5/16) and vests 1/48th per month for each month of service thereafter.